With preclinical trials already underway, psychedelic medicine firm Lobe Sciences is on the path to success

By Mark Sheridan


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.


Collaboration between under-the-radar R&D firm and Miami medical school could unlock the secret to solving the mental health crisis…

To understand one of the most exciting advantages under-the-radar Canadian R&D company Lobe Sciences (CSE:LOBE | OTC:GTSIF) has over its competition, you need to head over the Canadian border and way south…

To Florida, in fact.

And, specifically, to Miami.

You see, the University of Miami’s Miller School of Medicine is internationally recognised as a leader in medical research.

In 2019, it was awarded $149 million by the National Institutes of Health (NIH) to fund its work…

And it’s been ranked by the Blue Ridge Institute for Medical Research in the top 40 medical schools in America.

Bottom line is, it’s a good school.

But, crucially, the Miller School has a licence from the US Drug Enforcement Administration to conduct research using Schedule 1 controlled substances.

Why is this important?

Because it means it can carry out and support research into psychedelic drugs, such as psilocybin.

And it is exactly these types of psychedelic drugs that Lobe Sciences (CSE:LOBE | OTC:GTSIF) is using to help revolutionize the way we treat mental health disorders.

Indeed, the collaborative research between Lobe (CSE:LOBE | OTC:GTSIF) and the Miller School into post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) is already yielding very promising results.

However, with the psychedelics industry now taking off (it’s forecast to see a 16% rise year on year), numerous other companies are exploring new medical treatments too.

For many though, there’s a snag. Without the support of a licenced medical institution, the hope for FDA approval will likely remain just that…a hope.

Obviously, that is not the case for Lobe (CSE:LOBE | OTC:GTSIF).

Thanks to its special collaboration with the Miller School, it is already able to make excellent inroads towards the potentially transformative goal of FDA approval.


As you may know already, there are essentially four stages in what’s known as the FDA cycle: acquisition, discovery, clinical development, and approval.

Thanks to its acquisition of Eleusian Biosciences in July 2020, Lobe Sciences (CSE:LOBE | OTC:GTSIF) it already has five provisional patent applications for unique combinations of psychedelics and medical devices to be used in the treatment of PTSD and mTBI.

This makes it active in the acquisition stage.

This is good, but it is also where many companies can get stuck.

But not Lobe (CSE:LOBE | OTC:GTSIF).

It is now advancing into the second stage of discovery in two different ways.

First, there are the preclinical trials being carried out with the Miller School of Medicine. This is a huge step in itself.

But second, it is also carrying out additional work with San Diego engineering firm VisionWorks, developing new technology to actually apply its medicines and those of other companies.

It’s thanks to such exciting advances that Lobe (CSE:LOBE | OTC:GTSIF) is moving confidently along the path to FDA approval.

Yet what’s even more encouraging is the fact that the FDA has now granted ‘breakthrough therapy’ status to several clinical trials already using psilocybin (a key compound in psychedelic medicines) to treat severe treatment-resistant depression.

And, the US health regulatory has also agreed to give those suffering from PTSD greater access to MDMA-assisted psychotherapy.

These moves—together with various states in the US beginning to decriminalise the medicinal use of psilocybin—are all early signifiers of a much larger psychedelic medicine revolution afoot.

One that could eclipse the boom we saw when cannabis was widely legalised in the US a few years back.

What’s more, as you’ll see, the expert team behind Lobe (CSE:LOBE | OTC:GTSIF) is perfectly positioned to take advantage of what’s to come.


Proven experience in the business


Lobe Sciences’ (CSE:LOBE | OTC:GTSIF) Miller School collaboration gives it incredible access to the kind of research that many other companies just wouldn’t otherwise be able to get.

But the fact is, Lobe (CSE:LOBE | OTC:GTSIF) already has more than a few tricks up its sleeve where experience in the psychedelic medicine space is concerned.

For one, its recently appointed Chief Medical Officer, Maghsoud Dariani, is not only one of the most sought-after experts in psychedelic medicine, but—as president of Focus Pharmaceuticals—he has already managed the development and FDA approval of similar products.

As you can imagine, having someone on board who has already been through the entire FDA cycle and come out the other end successfully is a huge advantage for Lobe (CSE:LOBE | OTC:GTSIF).

And he’s not the only member of the team with proven experience in this still developing industry.

Mr Dariani is joined by the likes of seasoned CEO Tom Baird, internationally revered professor of psychiatry and neurosciences, Dr Mark A. Geyer, and Jonathan Gilbert, who himself has found a number of successful biotech companies.

When you consider their knowledge about psychedelics, together with their vast experience in steering such businesses to success, you realise just how exciting an opportunity Lobe (CSE:LOBE | OTC:GTSIF) represents.

And then, when you see that the company’s current valuation is under C$10 million in an industry where the average valuation is estimated to be around C$44 million, you realise just how smart an investment it could be right now.

Indeed, the rewards could be huge…

Both for Lobe Sciences (CSE:LOBE | OTC:GTSIF) and for those investors who are quickest to move.


The fact is, when it comes to what’s happening in the psychedelic medicine industry right now, it is not unreasonable to use words like revolution and transformation.

Big changes are on the horizon.

We’ve already seen how the FDA itself is embracing the science and how regulation is being reduced.

And we’ve seen the industry is already forecast to grow 16.3% year on year.

But the real reason this space is poised to explode is much more fundamental…

It’s because we are facing a global mental health crisis.

And it’s a very real challenge.

In fact, the World Health Organisation has called it a “silent epidemic”.

There’s no wonder when it’s estimated 13% of the global population suffer from some form of mental disorder.

That’s nearly a billion people.

And in the US alone, it’s thought that one in five have a mental health problem.

Yet, as it stands, there is no standard treatment for many of these conditions.

This is why so many people are keen to explore psychedelic medicine. It offers a potential way to help solve this crisis.

That’s why people are moving on this…

And it’s why they’re moving fast.

For example, one study showed up to 80% of cancer patients being micro-dosed with psychedelics demonstrated reduced stress and anxiety.

And another international study published in Psychopharmacology found 79% of participants felt their mental health improved as a result of microdosing psychedelic medicine.

These are promising results, but naturally, there is more work to be done and new breakthroughs are happening all the time.

However, one thing is very clear…

With so many people impacted by mental health issues around the world, the companies at the forefront of this coming revolution will surely reap the rewards.

Lobe Sciences (CSE:LOBE | OTC:GTSIF) is already demonstrating that it has both the scientific knowhow and business acumen to be one of the leaders.

And we’ve seen in its crucial collaboration with the Miller School on psychedelic medicines and its ongoing development of new delivery devices that it is making huge leaps forward.

Indeed, Lobe’s (CSE:LOBE | OTC:GTSIF) work is not just an exciting and potentially profitable prospect for investors…

It’s an extremely hopeful advance for all those around the world suffering with mental health issues.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Science Ltd. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of eighty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.


valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


In this article:

Author: Mark Sheridan

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter